1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Center for Breast Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
3Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
4Department of Radiation Oncology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea
5Department of Radiation Oncology, Kosin University Gospel Hospital, Busan, Korea
6Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
7Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea
8Department of Radiation Oncology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
9Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
10Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Korea
11Department of Radiation Oncology, Dong-A University Hospital, Dong-A University School of Medicine, Busan, Korea
12Department of Radiation Oncology, Chonbuk National University Medical School, Jeonju, Korea
13Department of Radiation Oncology, Wonju Severance Christian Hospital, Wonju, Korea
Copyright © 2019 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Values are presented as mean±standard deviation or number (%). BCS, breast conserving surgery; RT, radiation therapy; MRM, modified radical mastectomy; IDC, invasive ductal carcinoma; LN, lymph node; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; LVI, lymphovascular invasion; ECE, extracapsular extension.
Characteristic | Before matching |
After matching |
||||
---|---|---|---|---|---|---|
BCS+RT (n=1,047) | MRM alone (n=427) | p-value | BCS+RT (n=676) | MRM alone (n=398) | p-value | |
Age (yr) | 47.4±8.6 | 48.9±9.4 | 0.004 | 48.1±8.9 | 48.7±9.3 | 0.319 |
Menopausal status | ||||||
Premenopause | 676 (64.6) | 251 (58.8) | 0.043 | 415 (61.4) | 238 (59.8) | 0.604 |
Postmenopause | 371 (35.4) | 176 (41.2) | 261 (38.6) | 160 (40.2) | ||
Site | ||||||
Left | 504 (48.1) | 217 (50.8) | 0.380 | 330 (48.8) | 199 (50.0) | 0.732 |
Right | 543 (51.9) | 210 (49.2) | 346 (51.2) | 199 (50.0) | ||
Pathology | ||||||
IDC | 984 (94.0) | 413 (96.7) | 0.044 | 648 (95.9) | 384 (96.5) | 0.601 |
Non-IDC | 63 (6.0) | 14 (3.3) | 28 (4.1) | 14 (3.5) | ||
Pathologic T category | ||||||
1 | 507 (48.4) | 160 (37.5) | 0.000 | 280 (41.4) | 160 (40.2) | 0.897 |
2 | 532 (50.8) | 265 (62.1) | 393 (58.1) | 236 (59.3) | ||
3 | 8 (0.8) | 2 (0.5) | 3 (0.4) | 2 (0.5) | ||
No. of LN metastases | ||||||
1 | 603 (57.6) | 231 (54.1) | 0.070 | 381 (56.4) | 218 (54.8) | 0.722 |
2-3 | 444 (42.4) | 196 (45.9) | 295 (43.6) | 180 (45.2) | ||
LN management | ||||||
SLNB only | 78 (7.4) | 24 (5.6) | 0.258 | 46 (6.8) | 22 (5.5) | 0.438 |
ALND | 969 (92.6) | 403 (94.4) | 630 (93.2) | 376 (94.5) | ||
Positive LN ratio | ||||||
≤ 0.1 | 506 (48.3) | 233 (54.6) | 0.034 | 338 (50.0) | 219 (55.0) | 0.101 |
> 0.1 | 541 (51.7) | 194 (45.4) | 338 (50.0) | 179 (45.0) | ||
LVI | ||||||
No | 370 (35.3) | 273 (63.9) | 0.000 | 397 (58.7) | 244 (61.3) | 0.068 |
Yes | 677 (64.7) | 154 (36.1) | 279 (41.3) | 154 (38.7) | ||
Nuclear grade | ||||||
1-2 | 599 (57.2) | 200 (46.8) | 0.000 | 324 (47.9) | 200 (50.3) | 0.412 |
3 | 448 (42.8) | 227 (53.2) | 352 (52.1) | 198 (49.7) | ||
Histologic grade | ||||||
I-II | 642 (61.3) | 216 (50.6) | 0.000 | 301 (44.5) | 185 (46.5) | 0.482 |
III | 405 (38.7) | 211 (49.4) | 375 (55.5) | 213 (53.5) | ||
Molecular subtype | ||||||
Luminal A | 459 (43.8) | 192 (45.0) | 0.736 | 375 (55.4) | 216 (54.3) | 0.736 |
Non-luminal A | 588 (56.2) | 235 (55.0) | 301 (44.6) | 182 (45.7) | ||
ECE | ||||||
No | 578 (55.2) | 267 (62.5) | 0.012 | 382 (56.5) | 239 (60.1) | 0.247 |
Yes | 469 (44.8) | 160 (37.5) | 294 (43.5) | 159 (39.9) |
Sites of the first failure | BCS+RT (n=676) | MRM alone (n=398) | p-value |
---|---|---|---|
Isolated loco-regional only | 10 (1.5) | 6 (1.5) | 0.971 |
Local only | 5 (0.7) | 2 (0.5) | 1.000 |
Regional only | 5 (0.7) | 4 (1.0) | 0.733 |
Distant only | 28 (4.1) | 23 (5.8) | 0.223 |
Simultaneous loco-regional and distant | 12 (1.8) | 13 (3.3) | 0.118 |
Total | 50 (7.4) | 42 (10.6) | 0.074 |
Characteristic | Univariate analysis |
Multivariate analysis |
||
---|---|---|---|---|
5-Year OS rate (%) | p-value | HR (95% CI) | p-value | |
Age (yr) | ||||
≤ 55 | 97.7 | 0.828 | - | - |
> 55 | 97.5 | - | ||
Menopause status | ||||
Premenopause | 98.6 | 0.072 | 0.592 (0.295-1.190) | 0.141 |
Postmenopause | 96.0 | - | ||
Site | ||||
Left | 97.3 | 0.737 | - | - |
Right | 97.9 | - | ||
Pathology | ||||
IDC | 97.6 | 0.725 | - | - |
Non-IDC | 97.7 | - | ||
Pathologic T category | ||||
1 | 97.9 | 0.731 | - | - |
2-3 | 97.4 | - | ||
No. of LN metastases | ||||
1 | 97.8 | 0.443 | - | - |
2 | 97.4 | - | ||
LVI | ||||
No | 98.0 | 0.342 | - | - |
Yes | 97.2 | - | ||
Nuclear grade | ||||
1-2 | 98.9 | 0.002 | 0.544 (0.174-1.704) | 0.296 |
3 | 96.2 | - | ||
Histologic grade | ||||
I-II | 99.0 | 0.004 | 0.773 (0.269-2.220) | 0.632 |
III | 95.9 | - | ||
Molecular subtype | ||||
Luminal A | 99.1 | 0.001 | 0.327 (0.129-0.825) | 0.018 |
Non-luminal A | 96.3 | - | ||
ECE | ||||
No | 97.6 | 0.771 | - | - |
Yes | 97.7 | - | ||
Modality | ||||
BCS+RT | 98.6 | 0.088 | 0.597 (0.297-1.200) | 0.147 |
MRM alone | 96.1 | - |
Characteristic | Univariate analysis |
Multivariate analysis |
||
---|---|---|---|---|
5-Year DFS rate (%) | p-value | HR (95% CI) | p-value | |
Age (yr) | ||||
≤ 55 | 91.9 | 0.987 | - | - |
> 55 | 92.3 | - | ||
Menopause status | ||||
Premenopause | 92.5 | 0.248 | - | - |
Postmenopause | 91.0 | - | ||
Site | ||||
Left | 90.7 | 0.171 | 1.239 (0.818-1.875) | 0.311 |
Right | 93.2 | - | ||
Pathology | ||||
IDC | 91.9 | 0.598 | - | - |
Non-IDC | 93.2 | - | ||
Pathologic T category | ||||
1 | 95.0 | 0.001 | 0.665 (0.415-1.064) | 0.089 |
2-3 | 89.6 | - | ||
No. of LN metastases | ||||
1 | 93.2 | 0.126 | 0.823 (0.545-1.244) | 0.356 |
2-3 | 90.4 | - | ||
LVI | ||||
No | 94.6 | < 0.001 | 0.472 (0.304-0.731) | 0.001 |
Yes | 88.7 | - | ||
Nuclear grade | ||||
1-2 | 95.4 | < 0.001 | 0.715 (0.389-1.314) | 0.280 |
3 | 88.0 | - | ||
Histologic grade | ||||
I-II | 96.4 | < 0.001 | 0.254 (0.134-0.481) | 0.001 |
III | 86.1 | - | ||
Molecular subtype | ||||
Luminal A | 94.4 | 0.024 | 0.849 (0.544-1.326) | 0.472 |
Non-luminal A | 90.0 | - | ||
ECE | ||||
No | 91.8 | 0.771 | - | - |
Yes | 92.0 | - | ||
Modality | ||||
BCS+RT | 93.3 | 0.107 | 0.702 (0.463-1.065) | 0.096 |
MRM alone | 89.7 | - |
Characteristic | Univariate analysis |
Multivariate analysis |
||
---|---|---|---|---|
5-Year RFFS rate (%) | p-value | HR (95% CI) | p-value | |
Age (yr) | ||||
≤ 55 | 97.2 | 0.915 | - | - |
> 55 | 98.0 | - | ||
Menopause status | ||||
Premenopause | 97.3 | 0.571 | - | - |
Postmenopause | 97.4 | - | ||
Site | ||||
Left | 96.9 | 0.571 | - | - |
Right | 97.8 | - | ||
Pathology | ||||
IDC | 97.2 | 0.218 | - | - |
Non-IDC | 100 | - | ||
Pathologic T category | ||||
1 | 98.2 | 0.120 | 0.890 (0.417-1.900) | 0.764 |
2-3 | 96.7 | - | ||
No. of LN metastases | ||||
1 | 97.1 | 0.638 | - | - |
2-3 | 97.7 | - | ||
LVI | ||||
No | 98.6 | 0.004 | 0.340 (0.159-0.726) | 0.005 |
Yes | 95.9 | - | ||
Nuclear grade | ||||
1-2 | 98.8 | 0.021 | 0.527 (0.205-1.356) | 0.184 |
3 | 95.7 | - | ||
Histologic grade | ||||
I-II | 99.4 | < 0.001 | 0.138 (0.047-0.408) | < 0.001 |
III | 94.6 | - | ||
Molecular subtype | ||||
Luminal A | 98.5 | 0.193 | 0.902 (0.431-1.887) | 0.785 |
Non-luminal A | 96.4 | - | ||
ECE | ||||
No | 97.3 | 0.503 | - | - |
Yes | 97.3 | - | ||
Modality | ||||
BCS+RT | 98.3 | 0.102 | 0.523 (0.262-1.044) | 0.066 |
MRM | 95.7 | - |
Morbidity | BCS+RT (n=676) |
MRM alone (n=398) |
p-value | ||||
---|---|---|---|---|---|---|---|
Grade 1 | Grade ≥ 2 | Total | Grade 1 | Grade ≥ 2 | Total | ||
Lymphedema | 69 (10.2) | 22 (3.3) | 91 (13.5) | 26 (6.5) | 6 (1.5) | 32 (8.0) | 0.007 |
Pneumonitis | 8 (1.2) | 1 (0.1) | 9 (1.3) | 0 | 0 | 0 | 0.031 |
Values are presented as mean±standard deviation or number (%). BCS, breast conserving surgery; RT, radiation therapy; MRM, modified radical mastectomy; IDC, invasive ductal carcinoma; LN, lymph node; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; LVI, lymphovascular invasion; ECE, extracapsular extension.
Values are presented as number (%). BCS, breast conserving surgery; RT, radiation therapy; MRM, modified radical mastectomy.
OS, overall survival; HR, hazard ratio; CI, confidence interval; IDC, invasive ductal carcinoma; LN, lymph node; LVI, lymphovascular invasion; ECE, extracapsular extension; BCS, breast conserving surgery; RT, radiation therapy; MRM; modified radical mastectomy.
DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; IDC, invasive ductal carcinoma; LN, lymph node; LVI, lymphovascular invasion; ECE, extracapsular extension; BCS, breast conserving surgery; RT, radiation therapy; MRM; modified radical mastectomy.
RFFS, regional failure-free survival; HR, hazard ratio; CI, confidence interval; IDC, invasive ductal carcinoma; LN, lymph node; LVI, lymphovascular invasion; ECE, extracapsular extension; BCS, breast conserving; RT, radiation therapy; MRM; modified radical mastectomy.
Values are presented as number (%). BCS, breast conserving surgery; RT, radiation therapy; MRM, modified radical mastectomy.